Med BioGene Gets Additional Investment from SEP Capital | GenomeWeb

NEW YORK (GenomeWeb News) – Med BioGene today said that it has signed an agreement with SEP Capital to sell nearly C$500,000 (US$434,000) in units to the investment firm in a private placement.

The deal comes on the heels of Med BioGene raising C$1.6 million through a private placement last month of 20 million units in two tranches. The Vancouver, BC-based molecular diagnostics firm said that SEP will invest all of its available cash reserves — C$475,979 as of Dec. 31, 2008 — in the placement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genetic method to gauge age of ancient samples, genetic polymorphisms in mouse strain, and more.

Two Stanford professors are turning to the online game EteRNA to develop a new way to diagnose tuberculosis.

Lita Nelsen from the Massachusetts Institute of Technology's technology-transfer office is retiring after decades there.

After nine years, the Canadian government is loosening its restrictions on government scientists' ability to speak to the press and public.